Neurexis Therapeutics

Executive Summary

Neurexis Therapeutics is a privately-held biotechnology company founded in 2018 and headquartered in San Diego, CA, focused on developing neuroprotective therapies for central nervous system disorders characterized by neurodegeneration, including global cerebral ischemia, spinal cord ischemia, stroke, and Alzheimer's disease. The company's platform aims to address the unmet need for treatments that prevent long-lasting cognitive impairment following acute and chronic brain injuries. By targeting shared pathways of neurodegeneration, Neurexis seeks to improve outcomes for millions of patients who currently face persistent cognitive decline even after surviving the initial insult. The company's innovative approach leverages RNA and gene therapy modalities to deliver neuroprotective agents directly to affected neural tissues, potentially halting or reversing damage. As a preclinical-stage entity, Neurexis is poised to advance its lead candidate toward the clinic, with initial validation likely in acute indications where proof-of-concept can be established more rapidly. The company's scientific foundation and focus on high-unmet-need indications position it as a compelling opportunity in the neuroprotection space, though significant clinical and regulatory hurdles remain.

Upcoming Catalysts (preview)

• TBDLead Program IND Filing40% success
• TBDCompletion of GLP Toxicology Studies50% success
• TBDSeries B Financing Round60% success